RAD52 and lung cancer: Increasingly, immunotherapies are coming to the forefront of lung cancer therapy as both monotherapies and combination therapies [2, 32] and our data suggest that the increased cell death found in NTCU-treated Rad52−/− mouse lungs may be due to an altered immune response.